Artificial colloids versus human albumin for the treatment of ovarian hyperstimulation syndrome: A retrospective cohort study

Abstract

BackgroundThe optimal colloid solution for the treatment of ovarian hyperstimulation syndrome (OHSS) remains to be established.ObjectiveWe aimed to compare artificial colloids (AC) with human albumin (HA) for the treatment of OHSS.Materials and MethodsIn this retrospective cohort study, data for OHSS participants were collected from a national inpatient database in Japan. The participants received intravenous fluid management with AC (n = 156) or HA (n = 127). We compared the two groups in terms of the length of stay, development of post-treatment complications, and termination surgery.ResultsIn multivariable linear regression analyses for log-transformed length of stay with reference to the OHSS participants receiving AC, the regression coefficient (95% confidence interval) in participants receiving HA was 0.03 (-0.04-0.09, p = 0.42). Thromboembolism occurred in two participants in the HA group and three participants in the AC group. Two participants in the HA group suffered renal failure during hospitalization. No participants underwent termination surgery in the two groups.ConclusionThe present results showed comparable efficacy between AC and HA for the treatment of OHSS. There were no significant differences in post-treatment complications between the two groups.

<p>In vitro Fertilization Procedures with Embryo Transfer and Their Association with Thrombophilia, Thrombosis and Early Antithrombotic Treatments</p>

“…OHSS may be considered an occasional complication of pharmacological treatment of female infertility with exogenous gonadotropins. 12 It may be as high as 25% of all ovarian stimulation and it is associated with very high levels of serum estradiol (ie, >2500-3500 pg/mL) and to the presence of an increased number of ovarian follicles. 12 From a clinical point of view, OHSS is associated with nausea, vomiting, sudden weight increase, ascites and, rarely, to pleural effusion and thromboembolic complications.…”

“…12 It may be as high as 25% of all ovarian stimulation and it is associated with very high levels of serum estradiol (ie, >2500-3500 pg/mL) and to the presence of an increased number of ovarian follicles. 12 From a clinical point of view, OHSS is associated with nausea, vomiting, sudden weight increase, ascites and, rarely, to pleural effusion and thromboembolic complications. 13 Thromboembolic complications usually affect the venous system.…”

Ovarian Hyperstimulation: Diagnosis, Prevention, and Management

“…AC and HA have been compared with determine if one was superior to the other, though with inconsistent results. 80 In cases of persistent oliguria and normal hematocrit, diuretics have been suggested as a possible option to increase urine output, however, their use should be avoided due to their hemoconcentration effect. 13 Patients can be discharged once IV therapy can be switched to oral and they show an appropriate fluid balance in terms of both intake and output.…”

Letrozole and ovarian hyperstimulation syndrome: Retrospective cross-sectional study

“…Previous studies have introduced various drugs such as calcium, glucocorticoids, hydroxy ethyl starch, albumin, cabergoline, and letrozole for preventing OHSS. However, there is a disagreement regarding the effectiveness of these drugs in preventing OHSS, and a conclusive result is not established (7)(8)(9)(12)(13)(14). Letrozole is the third generation, non-steroidal aromatase inhibitor binding reversibly to the aromatase enzyme; thereby inhibiting the conversion of androgen to estrogen and reducing blood estradiol levels by approximately 98%.…”